Check Out Our CD40 mAb Phase II Poster at ASCO2024!
ASCO 2024 | Biocytogen/Eucure Biopharma to Present Two Phase II Clinical Studies of CD40 Agonistic Antibody YH003 Biocytogen’s wholly owned subsidiary Eucure Biopharma today…
Read more
Join us at Booth D23 at BIO KOREA 2024! May 8-10
Biocytogen’s APAC business development team is excited to exhibit and host 1-on-1 meetings at BIO KOREA 2024, taking place from May 8-10, 2024 in Seoul,…
Read more
April 2024 Newsletter
New Animal Models Humanized Immune-Checkpoint Mice Product Catalog Number B-hCRTAM mice 112532 B-hCD28/hGPC3 mice 113297 B-hMICB mice 112152 B-hRAGE mice plus 113157 B-hCD3E/hCD79B mice 113312…
Read more
Immuno-Oncology Summit Europe 2024: April 23-25
Visit Our Bispecific Antibody Poster at IO Summit Europe 2024! Biocytogen’s antibody Business Development & Licensing team is excited to attend the upcoming Immuno-Oncology…
Read more
Festival of Biologics USA 2024: April 15-17
Thank you to those who joined us at the Festival of Biologics USA 2024 from April 15-17 in San Diego, CA! Our Poster titled…
Read more
Biocytogen’s Antibody Partner Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024
On April 7, at AACR, our therapeutic antibody collaborator Syncromune delivered an oral presentation unveiling clinical data of its SYNC-T technology for the first time!…
Read more
Webinar: Empowering Discovery and Development of Bispecific ADCs With a Common Light Chain Antibody Library and a Novel Linker/Payload
About the webinar Bispecific ADCs are a growing trend in the ADC field, offering improved efficacy and safety for the treatment of heterogeneous solid…
Read more
AACR 2024 Posters
We are thrilled to have had the opportunity to attend the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA. Your…
Read more
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates
Beijing, China, March 25, 2024 --Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel…
Read more
BIO-Europe Spring 2024 | Schedule 1-on-1 Meetings with Biocytogen
Biocytogen’s antibody BD and licensing team is pleased to attend and host 1-on-1 meetings at BIO-Europe Spring, taking place March 18-20, 2024 in Barcelona, Spain.…
Read more